Polymorphic salt as medicine for migraine
The present invention is concerned with a crystalline, polymorphic form of a compound of formula (I)characterized by a powder X-ray diffraction pattern obtained using copper K-alpha1 radiation (lambd=0.15046 nm) which shows main peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98,...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English |
Published |
14.08.2002
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention is concerned with a crystalline, polymorphic form of a compound of formula (I)characterized by a powder X-ray diffraction pattern obtained using copper K-alpha1 radiation (lambd=0.15046 nm) which shows main peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70, 21.29, 21.45, 22.21, 22.64, 23.08, 25.20 and 25.79.The invention also relates to processes for the preparation of said form, to pharmaceutical compositions containing same and to its use in medicine, particularly the treatment of conditions for which an agonist of 5-HT1 receptors is indicated, for example, migraine. |
---|---|
Bibliography: | Application Number: CN20008010798 |